Avipep’s experienced management team is highly regarded in the fields of immunology, oncology, clinical research and radio-imaging.
Peter Hudson, PhD, Chief Scientific Officer
Peter was co-founder of Avipep as one of the key inventors of the Avibody™ platform technology. He has over 25 years of experience in protein (biopharmaceutical) design and production with over 14 Patent Applications and +100 publications. Peter has a PhD (Cambridge) and B.Sc (Hons-Adelaide) is an elected Fellow of the ATSE Academy. Peter founded the Victorian Biologics Consortium to leverage Government and Wellcome Trust UK investments of over $4million, through Avipep. Peter previously led CSIRO’s Neuroscience Theme and a $10 million 3-year AIBL study of Alzheimer’s disease (2007-2010). He was the founding Deputy CEO and Scientific Director of the CRC for Diagnostics, an $8 million per annum research portfolio (1995-2006).
Jeremy Wu, PhD, Research Manager
Jeremy has over 20 years of experience in pharmaceutical and biotech industry and has held research and management positions with a number of Australian biotech companies including Mimotopes, Starpharma and Avipep. His drug research and development expertise includes synthesis of heterocyclic compounds of biological importance, natural product elucidation, combinatorial chemistry, dendrimer chemistry and antibody-drug conjugates. He has over 20 publications and 3 patents. Jeremy received his PhD from University of Wollongong and then did postdoctoral training in Research School of Chemistry at the Australian National University.
Geoffrey Pietersz, PhD
Prof Pietersz obtained his BSc (Hons) and PhD at the University of Melbourne in synthetic organic chemistry in the area of natural products. He is an expert in Bio-Organic Chemistry with more than 35 years’ experience working on cancer/infectious disease vaccines and monoclonal antibodies, drug/toxin/radio-nucleotide antibody conjugates, their characterisation and measurement of anti-tumour efficacy. He has more than 160 peer-reviewed publications and many granted patents in the areas of cancer, inflammation and infectious diseases. He is currently at the Baker IDI and Chief Technology Officer for Ascend Biopharmaceuticals Ltd. He is a research associate of the Burnet Institute and holds Adjunct Professorial appointments at Melbourne, Monash and Victoria University.
Clement Leong, PhD, Executive Chairman
Clement has more than 18 years of biotech, pharma and venture capital experience in Australia and the United States, with companies such as Merck Biopharma (formerly Schering-Plough BioPharma in Palo Alto, California), Entelos Inc. in Foster City, California and SciVentures Investments in Melbourne, Australia. During this period he actively led multiple development programs and completed a series of financing and licensing transactions. He was the founding chairman of Ascend and has led the Company’s clinical and preclinical programs. He has also been involved in the mezzanine funding of a number of ASX listed Australian biotech companies (e.g., Evogenix, ASX: EGX and Patrys Pty Ltd, ASX: PAB) and was the founding investor and an executive director in a number of private Australian biotech and medical device companies. Clement earned his PhD from the Department of Medicine at the University of Western Australia and an MBA from the Australian Graduate School of Management (AGSM).
Ross Chessari, Director
Ross is a seasoned investor in antibody development. He also co-founded SciVentures Investments and, as Director of McMillan Shakespeare (ASX:MMS), led the MBO and listing. He has been responsible for the management and administration of $15 Billion of funds as Managing Director of ANZ Asset management and as the General Manager of ANZ Trustees. Ross has academic qualifications as Bachelor of Laws and a Masters of Taxation, both from the University of Melbourne.
Graham Mitchell, PhD, Director
Graham is recognised as one of Australia’s leading biological scientists. His expertise extends over a wide range of science and technology. He has detailed knowledge of the academia-industry interface, has worked in many overseas countries and been involved with tropical disease programs of the World Health Organisation for many years. He has been an advisor on innovation to the Victorian, Commonwealth, Tasmanian and Northern Territory Governments. In another government role the Principals of Foursight, including Mitchell, jointly act as Chief Scientist for the Victorian Department of Economic Development and Department of Environment. He is a non-executive director of Antisense Therapeutics Limited, Avipep Pty Ltd, WEHI and has been a Principal of Foursight, an advisory service in science, technology, innovation and commercialisation, since 1996. He is an author of more than 350 publications, has received numerous awards for scientific achievements and, in 1993, was appointed an Officer in the Order of Australia for services to science.